About: covid:PMC7242960

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7242960 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Zangrillo, Alberto De Cobelli, Francesco Baldissera, Elena Boffini, Nicola Campochiaro, Corrado Castagna, Antonella Cavalli, Giulio Dagna, Lorenzo De Luca, Giacomo Della-Torre, Emanuel Monti, Giacomo Ripa, Marco Rovere-Querini, Patrizia Ruggeri, Annalisa Tomelleri, Alessandro Tresoldi, Moreno
is schema:about of	named entity 'patients' named entity 'retrospective cohort study' named entity 'CRP' named entity 'Tocilizumab' named entity 'chest X-ray' named entity 'treatment group' named entity 'antibiotic therapy' named entity 'computed tomography (CT) scan' named entity 'oxygen' named entity 'informed consent' named entity 'tocilizumab' named entity 'antigen' named entity 'adverse events' named entity 'tocilizumab' named entity 'pneumonia' named entity 'tocilizumab' named entity 'receptor' named entity 'ClinicalTrials.gov' named entity 'ICU' named entity 'IL-18' named entity 'Non-invasive Ventilation' named entity 'treatment group' named entity 'ICU' named entity 'ICU' named entity '1.000' named entity 'tocilizumab' named entity 'inflammatory markers' named entity 'follow-up' named entity 'hazard ratio' named entity 'intravenous' named entity 'Italy' named entity 'mechanical ventilation' named entity 'statistically significant' named entity 'FiO2' named entity 'enoxaparin' named entity 'FiO2' named entity 'high fever' named entity 'clinical outcomes' named entity 'ICU' named entity 'COVID' named entity '28 days' named entity 'NIV' named entity 'tocilizumab' named entity 'long-term' named entity 'Milan' named entity 'Italian' named entity 'COVID' named entity 'IL-6' named entity 'standard treatment' named entity 'Lombardy' named entity 'adverse events' named entity 'ICU' named entity 'invasive ventilation' named entity 'COVID' named entity 'tocilizumab' named entity 'fatigue' named entity 'ICU' named entity 'treatment group' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'LDH' named entity 'clinical trials' named entity 'placebo-controlled trials' named entity 'Italy' named entity 'pneumothorax' named entity 'anti-inflammatory drugs' named entity 'fraction of inspired oxygen' named entity 'tocilizumab' named entity 'Bacteremia' named entity 'tocilizumab' named entity 'Figure 1' named entity 'clinical trials' named entity 'randomized controlled trials' named entity 'follow-up' named entity 'invasive mechanical ventilation' named entity 'COVID' named entity 'CRS' named entity 'pneumothorax' named entity 'Italy' named entity 'administrated' named entity 'aspartate aminotransferase' named entity 'Polymerase Chain Reaction' named entity '95% confidence interval'

Attributes

Values

Creator

Zangrillo, Alberto
De Cobelli, Francesco
Baldissera, Elena
Boffini, Nicola
Campochiaro, Corrado
Castagna, Antonella
Cavalli, Giulio
Dagna, Lorenzo
De Luca, Giacomo
Della-Torre, Emanuel
Monti, Giacomo
Ripa, Marco
Rovere-Querini, Patrizia
Ruggeri, Annalisa
Tomelleri, Alessandro
Tresoldi, Moreno

is schema:about of

named entity 'patients'
named entity 'retrospective cohort study'
named entity 'CRP'
named entity 'Tocilizumab'
named entity 'chest X-ray'
named entity 'treatment group'
named entity 'antibiotic therapy'
named entity 'computed tomography (CT) scan'
named entity 'oxygen'
named entity 'informed consent'
named entity 'tocilizumab'
named entity 'antigen'
named entity 'adverse events'
named entity 'tocilizumab'
named entity 'pneumonia'
named entity 'tocilizumab'
named entity 'receptor'
named entity 'ClinicalTrials.gov'
named entity 'ICU'
named entity 'IL-18'
named entity 'Non-invasive Ventilation'
named entity 'treatment group'
named entity 'ICU'
named entity 'ICU'
named entity '1.000'
named entity 'tocilizumab'
named entity 'inflammatory markers'
named entity 'follow-up'
named entity 'hazard ratio'
named entity 'intravenous'
named entity 'Italy'
named entity 'mechanical ventilation'
named entity 'statistically significant'
named entity 'FiO2'
named entity 'enoxaparin'
named entity 'FiO2'
named entity 'high fever'
named entity 'clinical outcomes'
named entity 'ICU'
named entity 'COVID'
named entity '28 days'
named entity 'NIV'
named entity 'tocilizumab'
named entity 'long-term'
named entity 'Milan'
named entity 'Italian'
named entity 'COVID'
named entity 'IL-6'
named entity 'standard treatment'
named entity 'Lombardy'
named entity 'adverse events'
named entity 'ICU'
named entity 'invasive ventilation'
named entity 'COVID'
named entity 'tocilizumab'
named entity 'fatigue'
named entity 'ICU'
named entity 'treatment group'
named entity 'tocilizumab'
named entity 'tocilizumab'
named entity 'tocilizumab'
named entity 'LDH'
named entity 'clinical trials'
named entity 'placebo-controlled trials'
named entity 'Italy'
named entity 'pneumothorax'
named entity 'anti-inflammatory drugs'
named entity 'fraction of inspired oxygen'
named entity 'tocilizumab'
named entity 'Bacteremia'
named entity 'tocilizumab'
named entity 'Figure 1'
named entity 'clinical trials'
named entity 'randomized controlled trials'
named entity 'follow-up'
named entity 'invasive mechanical ventilation'
named entity 'COVID'
named entity 'CRS'
named entity 'pneumothorax'
named entity 'Italy'
named entity 'administrated'
named entity 'aspartate aminotransferase'
named entity 'Polymerase Chain Reaction'
named entity '95% confidence interval'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software